Literature DB >> 31525634

Oxytocin is a principal hormone that exerts part of its effects by active fragments.

Kerstin Uvnäs Moberg1, Linda Handlin2, Kathleen Kendall-Tackett3, Maria Petersson4.   

Abstract

Oxytocin is a nonapeptide consisting of a cyclic six amino-acid structure and a tail of three amino acids. It was originally known for its ability to induce milk ejection and to stimulate uterine contractions. More recently, oxytocin has been shown to stimulate social behaviors, and exert pain-relieving, anti-stress/anti-inflammatory and restorative effects. We hypothesize that oxytocin is a principal hormone that, in part, exerts its effects after degradation to active fragments with more specific effect profiles. Experimental findings on rats show that administered oxytocin exerts biphasic effects. For example, after an initial increase in pain threshold, a second more long-lasting increase follows. Blood pressure and cortisol levels initially increase and then reverse into a long-lasting decrease in blood pressure and cortisol. Whereas the initial effects are, the second-phase effects are not blocked by an oxytocin antagonist, but by an opioid mu-antagonist and by an alpha 2-adrenoreceptor antagonist, respectively, suggesting that other receptors are involved. Repeated administration of oxytocin induces multiple anti-stress effects, which are mediated by alpha 2-adrenoreceptors. Repeated administration of linear oxytocin and linear oxytocin fragments with a retained C-terminal reduce spontaneous motor activity, a sedative or anti-stress effect, suggesting that alpha 2-adrenoreceptors have been activated. In contrast, linear mid-fragments stimulate motor activity. Low-intensity stimulation of cutaneous nerves in rats, as well as breastfeeding and skin-to-skin contact between mothers and babies, trigger immediate anti-stress effects. Some of these effects are likely caused by open ring/linear C-terminal fragments activating alpha 2-adrenoreceptors. Oxytocin fragments may be pre-formed and released in the brain or created by metabolic conversion of the principal hormone oxytocin in the central nervous system. Oxytocin and its fragments may also be released from peripheral sites, such as peripheral nerves, the gastrointestinal tract, and blood vessels in response to decreased sympathetic or increased parasympathetic nervous tone. Smaller fragments of oxytocin produced in the periphery may easily pass the blood-brain barrier to induce effects in the brain. In conclusion, oxytocin is linked to many different, sometimes opposite effects. The intact cyclic molecule may act to initiate social interaction and associated psychophysiological effects, whereas linear oxytocin and C-terminal fragments may induce relaxation and anti-stress effects following social interaction. In this way, the principal hormone oxytocin and its fragments may take part in a behavioral sequence, ranging from approach and interaction to calm and relaxation. Linear fragments, with an exposed cysteine-residue, may exert anti-inflammatory and antioxidant effects and thereby contribute to the health-promoting effects of oxytocin.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31525634     DOI: 10.1016/j.mehy.2019.109394

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  19 in total

1.  The Association Between Peripheral Oxytocin Levels and Depressive Symptoms in People With HIV.

Authors:  Destin D Shortell; Leah H Rubin; Aidan J Murphy; Ronald A Cohen; Eric C Porges
Journal:  Psychosom Med       Date:  2022-08-16       Impact factor: 3.864

Review 2.  The Role of Kisspeptin in the Pathogenesis of Pregnancy Complications: A Narrative Review.

Authors:  Magdalena Szydełko-Gorzkowicz; Elżbieta Poniedziałek-Czajkowska; Radzisław Mierzyński; Maciej Sotowski; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

Review 3.  Neuronal-Immune Cell Units in Allergic Inflammation in the Nose.

Authors:  Vladimir Klimov; Natalia Cherevko; Andrew Klimov; Pavel Novikov
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 4.  Oxytocin and love: Myths, metaphors and mysteries.

Authors:  C Sue Carter
Journal:  Compr Psychoneuroendocrinol       Date:  2021-12-27

5.  Episodes of monocular blurring of vision during breastfeeding.

Authors:  Petros Petrou; Kelly Giannopoulou; Evangelia Papakonstantinou; Aristotelis Karamaounas; Stylianos Kandarakis; Ilias Georgalas
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-24

Review 6.  The Role of Affectionate Caregiver Touch in Early Neurodevelopment and Parent-Infant Interactional Synchrony.

Authors:  Sofia Carozza; Victoria Leong
Journal:  Front Neurosci       Date:  2021-01-05       Impact factor: 4.677

7.  The Effects of Intranasal Oxytocin on Neural and Behavioral Responses to Social Touch in the Form of Massage.

Authors:  Yuanshu Chen; Qin Li; Qianqian Zhang; Juan Kou; Yingying Zhang; Han Cui; Jennifer Wernicke; Christian Montag; Benjamin Becker; Keith M Kendrick; Shuxia Yao
Journal:  Front Neurosci       Date:  2020-12-04       Impact factor: 4.677

8.  The Oxytocinergic System as a Mediator of Anti-stress and Instorative Effects Induced by Nature: The Calm and Connection Theory.

Authors:  Patrik Grahn; Johan Ottosson; Kerstin Uvnäs-Moberg
Journal:  Front Psychol       Date:  2021-07-05

Review 9.  Is Oxytocin "Nature's Medicine"?

Authors:  C Sue Carter; William M Kenkel; Evan L MacLean; Steven R Wilson; Allison M Perkeybile; Jason R Yee; Craig F Ferris; Hossein P Nazarloo; Stephen W Porges; John M Davis; Jessica J Connelly; Marcy A Kingsbury
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  Neonatal Suckling, Oxytocin, and Early Infant Attachment to the Mother.

Authors:  Raymond Nowak; Frédéric Lévy; Elodie Chaillou; Fabien Cornilleau; Juliette Cognié; Pierre-Guy Marnet; Peter D Williams; Matthieu Keller
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-08       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.